树突状细胞肿瘤疫苗抗肿瘤研究进展  

Recent progress in research of dendritic cell-based tumor vaccine

作　　者：孟冉冉[1] 张跃伟[1] 赵广生[1] 张宁[2] 

机构地区：[1]大连大学附属中山医院介入治疗科,辽宁大连116001 [2]大连大学医学院临床医学系,辽宁大连116622

出　　处：《中华肿瘤防治杂志》2012年第20期1597-1600,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：大连市科技局项目(2010E15SF180)

摘　　要：目的:探讨不同树突状细胞(DC)肿瘤疫苗的抗肿瘤机制及应用价值。方法:应用NCBI的PubMed文献数据库系统,以"树突状细胞、疫苗、肿瘤"为关键词检索2001-01-01-2011-12-31文献1 589篇,纳入标准:1)DC抗肿瘤的机制;2)肿瘤抗原肽负载的DC肿瘤疫苗;3)肿瘤全细胞抗原负载的DC肿瘤疫苗;4)肿瘤细胞来源的基因修饰的DC肿瘤疫苗;5)DC-CIK联合修饰疫苗。根据纳入标准符合分析的共30篇文献纳入分析。结果:DC是目前已知人体内功能最强抗原提呈作用的专职抗原呈递细胞,与肿瘤发展有着密切的关系,以DC为基础制备的不同类型肿瘤疫苗提高了抗肿瘤免疫反应,但存在不同的缺点。结论:DC肿瘤疫苗展示了良好的应用前景,对临床免疫治疗将有着积极的作用,但仍有待于进一步深入研究。OBJECTIVE：To explore the different antitumor mechanisms and applications of dendritic cell （DC） tumor vaccine. METHODS： Totally 1 589 references were searched by using NCBI PubMed database system from2001-01-01 to 2011-12-31. The＂dendritic cell,vaccine, tumor＂ were used as key words and the inclusion criteria was as follows： 1） DC antitumor mechanism; 2） tumor antigen peptide load of DC tumor vaccine; 3） total tumor cell antigen loading of DC tumor vaccine; 4） tumor cells as a source of gene modified DC tumor vaccine; 5）modified DC-CIK combined vaccine. Thir- ty articles were analysed according to inclusion criteria. RESULTS：DC is the most powerful professional antigen-presenting cell. DC has a close relationship with tumor development. DC-based vaccines enhance the antitumor immune response,but different vaccines have different weaknesses. CONCLUSION：DC tumor vaccine shows a good prospect in clinical applica tions and plays a positive role in the clinical immune therapy,but still needs to be further studied.

关 键 词：树突状细胞 疫苗 肿瘤 研究进展 综述文献 

分 类 号：R730.51[医药卫生—肿瘤]